The global market for COVID-19 vaccine packaging and delivery devices is poised for sustained growth, forecasted to expand from USD 1,261.7 million in 2025 to USD 2,436.1 million by 2035, at a CAGR of ...

LAS CRUCES, NEW MEXICO / ACCESS Newswire / April 29, 2025 / As newly appointed CMS Administrator Dr. Mehmet Oz renews focus ...

New manufacturing deal positions CBDL to tap into the $4.9 billion Latin American CBD market, unlocking major revenue growth ...

Biomanufacturers producing protein biologics including complex modalities, will have access to a full suite of custom cell ...

VANCOUVER, BC / ACCESS Newswire / April 29, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), provides an update on its renewed engagement of Rumble Strip Media ...

StudyAbivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis 29.04.2025 / 22:05 CET/CESTThe issuer is solely ...

Independent Surveys Rank Top ASC Vendors for Client Satisfaction and User Experience Across 18 Key Performance Indicators DENVER, CO / ACCESS Newswire / April 29, 2025 / Black Book Research, the ...

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for ...

Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical ...

LOS GATOS, CA / ACCESS Newswire / April 29, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) ...

Takeda (TSE:4502/NYSE:TAK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the extension of the ...

Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets several pathways relevant for AD but distinct from current treatments ...